IMMUNOTHERAPY DECREASES ANTIGEN-INDUCED EOSINOPHIL CELL-MIGRATION INTO THE NASAL CAVITY
IMMUNOTHERAPY DECREASES ANTIGEN-INDUCED EOSINOPHIL CELL-MIGRATION INTO THE NASAL CAVITY
复制标题
DOI：
10.1016/0091-6749(91)90297-2
复制
发表时间：
1991-07-01
影响因子：
14.2
通讯作者：
NACLERIO, RM
中科院分区：
文献类型：
--
作者：
FURIN, MJ;NORMAN, PS;NACLERIO, RM
我们研究了免疫治疗（IT）对豚草抗原鼻腔激发后和季节性暴露期间嗜酸性粒细胞（EOS）迁移到鼻腔的影响。在第一项研究中，三组受试者参与：一组未接受治疗（N = 19），一组接受10个月IT，在2 μ g Amb a I（抗原E）时达到维持水平（N = 15），一组接受22个月IT，在24 μ g Amb a I时达到维持水平（N = 10）。在用豚草提取物鼻腔激发前和激发后24小时的12月期间进行的鼻灌洗中EOS的百分比被确定。攻毒前组间无显著差异。未治疗组的EOS百分比从26%显著增加至69.5%（p < 0.008），而治疗组无显著变化。在第二项研究中，根据Amb a I的维持剂量（微克）和治疗持续时间将45名患者分为四组：（1）未治疗（N = 15），（2）2 μ g治疗1年（N = 13），（3）2 μ g治疗2年（N = 11），（4）24 μ g治疗3年（N = 9）。鼻粘膜刷在拉格周季节进行。与对照组相比，IT治疗3年的个体中EOS的百分比显著更小（18 vs 8.4; p < 0.04）。与未给药组相比，较小剂量的IT（无论持续时间如何）未显示降低。这些研究提供的证据表明，IT修改嗜酸性粒细胞抗原暴露的反应，并证明在体内激发和季节性暴露之间的平行。
We investigated the effect of immunotherapy (IT) on eosinophil (EOS) migration into the nasal cavity after nasal provocation with ragweed antigen and during seasonal exposure. In the first study, three groups of subjects participated: one group with no treatment (N = 19), one group with 10 months of IT, reaching maintenance at 2-mu-g of Amb a I (antigen E) (N = 15), and one group with 22 months of IT, reaching maintenance at 24-mu-g of Amb a I (N = 10). The percent of EOSs in nasal lavages performed during December before and 24 hours after nasal challenge with ragweed extract was determined. No significant difference between groups existed before challenge. The no-treatment group demonstrated a significant increase in the percent of EOSs from 26% to 69.5% (p < 0.008), whereas the treated groups demonstrated no significant change. In the second study, 45 patients were divided into four groups based on maintenance dose in micrograms of Amb a I and duration of treatment: (1) no treatment (N = 15), (2) 1 year at 2-mu-g (N = 13), (3) 2 years at 2-mu-g (N = 11), and (4) 3 years at 24-mu-g (N = 9). Nasal mucosal brushings were done during the ragweek season. A significantly smaller percentage of EOSs in 3-year IT-treated individuals was obtained compared to the control group (18 versus 8.4; p < 0.04). The smaller dose of IT, regardless of duration, did not reveal a reduction compared to that in the no-treatment group. These studies provide evidence that IT modifies the eosinophilic response to antigen exposure and demonstrate a parallel between in vivo provocation and seasonal exposure.